These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 9516090)

  • 1. Effect of smaller droplet size of dornase alfa on lung function in mild cystic fibrosis. Dornase Alfa Nebulizer Group.
    Geller DE; Eigen H; Fiel SB; Clark A; Lamarre AP; Johnson CA; Konstan MW
    Pediatr Pulmonol; 1998 Feb; 25(2):83-7. PubMed ID: 9516090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small airway deposition of dornase alfa during exacerbations in cystic fibrosis; a randomized controlled clinical trial.
    Bakker EM; Volpi S; Salonini E; Müllinger B; Kroneberg P; Bakker M; Hop WC; Assael BM; Tiddens HA
    Pediatr Pulmonol; 2014 Feb; 49(2):154-61. PubMed ID: 23913868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities.
    Quan JM; Tiddens HA; Sy JP; McKenzie SG; Montgomery MD; Robinson PJ; Wohl ME; Konstan MW;
    J Pediatr; 2001 Dec; 139(6):813-20. PubMed ID: 11743506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aerosolized dornase alfa in cystic fibrosis: is there a role in the management of patients with early obstructive lung disease?
    Geller DE
    Pediatr Pulmonol; 1997 Aug; 24(2):155-8; discussion 159-61. PubMed ID: 9292913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of three jet nebulizer aerosol delivery systems used to administer recombinant human DNase I to patients with cystic fibrosis. The Pulmozyme rhDNase Study Group.
    Fiel SB; Fuchs HJ; Johnson C; Gonda I; Clark AR
    Chest; 1995 Jul; 108(1):153-6. PubMed ID: 7606951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An evaluation of two aerosol delivery systems for rhDNase.
    Shah PL; Scott SF; Geddes DM; Conway S; Watson A; Nazir T; Carr SB; Wallis C; Marriott C; Hodson ME
    Eur Respir J; 1997 Jun; 10(6):1261-6. PubMed ID: 9192926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group.
    McCoy K; Hamilton S; Johnson C
    Chest; 1996 Oct; 110(4):889-95. PubMed ID: 8874241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aerosolized dornase alfa (rhDNase) for therapy of cystic fibrosis.
    Hodson ME
    Am J Respir Crit Care Med; 1995 Mar; 151(3 Pt 2):S70-4. PubMed ID: 7881698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dornase alfa for cystic fibrosis.
    Yang C; Montgomery M
    Cochrane Database Syst Rev; 2018 Sep; 9(9):CD001127. PubMed ID: 30187450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis.
    Fitzgerald DA; Hilton J; Jepson B; Smith L
    Pediatrics; 2005 Oct; 116(4):e549-54. PubMed ID: 16147970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dornase alfa for cystic fibrosis.
    Yang C; Montgomery M
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD001127. PubMed ID: 33735508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial of efficacy and safety of dornase alfa delivered by eRapid nebulizer in cystic fibrosis patients.
    Sawicki GS; Chou W; Raimundo K; Trzaskoma B; Konstan MW
    J Cyst Fibros; 2015 Nov; 14(6):777-83. PubMed ID: 25921451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dornase alfa for cystic fibrosis.
    Yang C; Chilvers M; Montgomery M; Nolan SJ
    Cochrane Database Syst Rev; 2016 Apr; 4():CD001127. PubMed ID: 27043279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhaled mannitol for cystic fibrosis.
    Nevitt SJ; Thornton J; Murray CS; Dwyer T
    Cochrane Database Syst Rev; 2020 May; 5(5):CD008649. PubMed ID: 32358807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Respiratory evolution of patient with mucoviscidosis treated with mucolytic agents plus dornase alfa].
    Derelle J; Bertolo-Houriez E; Marchal F; Weber M; Virion JM; Vidailhet M
    Arch Pediatr; 1998 Apr; 5(4):371-7. PubMed ID: 9759155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dornase alfa. A review of its pharmacological properties and therapeutic potential in cystic fibrosis.
    Bryson HM; Sorkin EM
    Drugs; 1994 Dec; 48(6):894-906. PubMed ID: 7533697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhaled mannitol for cystic fibrosis.
    Nevitt SJ; Thornton J; Murray CS; Dwyer T
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD008649. PubMed ID: 29424930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does the timing of inhaled dornase alfa matter?
    van der Giessen L
    J Cyst Fibros; 2009 Jun; 8 Suppl 1():S6-9. PubMed ID: 19460684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dornase alfa as postoperative therapy in cystic fibrosis sinonasal disease.
    Cimmino M; Nardone M; Cavaliere M; Plantulli A; Sepe A; Esposito V; Mazzarella G; Raia V
    Arch Otolaryngol Head Neck Surg; 2005 Dec; 131(12):1097-101. PubMed ID: 16365224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhaled mannitol for cystic fibrosis.
    Nolan SJ; Thornton J; Murray CS; Dwyer T
    Cochrane Database Syst Rev; 2015 Oct; (10):CD008649. PubMed ID: 26451533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.